# Marksans Pharma: how the business works

> For learning only. Cityfort is not a SEBI-registered adviser and does not recommend buying or selling any security. Prices shown are dated and may be out of date.

Marksans Pharma Limited · NSE: MARKSANS · BSE: 524404 · Sector: Healthcare

Updated for Q2 FY27 · checked 12 Nov 2026

This is the plain-text version of https://cityfort.in/stocks/marksans-pharma. Source ids in [brackets] refer to the list at the end. Credit: "Cityfort, Marksans Pharma: how the business works", with the page URL.

## In short

Shop chains and other buyers in the US, UK, Europe and Australia pay Marksans for the generic medicines it makes; materials take the biggest share, and ₹13.8 of every ₹100 that came in was left as profit in FY26.

- In FY26 customers in the US and North America gave 52.0% of Marksans' revenue, Europe and the UK 34.4%, Australia and New Zealand 10.3% and other countries 3.4%.
- Of every ₹100 that came in during FY26, ₹42.1 went on materials and goods bought for resale, ₹21.5 on other running costs and ₹13.9 on staff (Cityfort calculation).

## Key facts

**What does Marksans Pharma do?**

Marksans Pharma Ltd, a Mumbai company incorporated in 1992, makes generic medicines such as painkillers and cough-and-cold products at four plants, two in Goa and one each in the US and the UK. Marksans Pharma sells them mainly in the US, the UK, Europe and Australia, and its FY26 revenue was ₹2,951 crore. [S1, S35]

**How does Marksans Pharma make money?**

Marksans Pharma earns most of its money from medicines sold without a prescription: its presentation put over-the-counter (OTC) products at 80.0% of FY26 revenue and prescription medicines at 20.0%. Pain-management products sold ₹1,311 crore in FY26, 44.4% of Marksans Pharma's revenue (Cityfort calculation from the company's presentation). [S17]

**Who are Marksans Pharma's customers?**

Marksans Pharma makes medicines that retail chains sell under their own brands; CARE Ratings said in Oct 2025 that retail chains gave nearly 80% of Marksans Pharma's US OTC revenue in FY25. In FY26 two unnamed customers together gave ₹679 crore, or 23.0% of Marksans Pharma's revenue. [S35, S1]

**How big is Marksans Pharma?**

In FY26 Marksans Pharma earned ₹2,951 crore of revenue and ₹418 crore of net profit for its shareholders, against ₹2,623 crore and ₹381 crore in FY25. The FY26 annual report says the Marksans Pharma group has more than 2,000 employees. [S1]

**Who owns Marksans Pharma?**

On 30 Sep 2026 the promoter group held 43.87% of Marksans Pharma, almost all of it (43.80%) in founder Mark Saldanha's name, with no shares pledged. OrbiMed Asia IV Mauritius held 8.62%, foreign portfolio investors 10.44%, Indian institutions 5.54% and other shareholders 31.53%. [S34]

**How did Marksans Pharma do in Q2 FY27?**

In Q2 FY27 (Jul–Sep 2026) Marksans Pharma's revenue was ₹940 crore, up 30.5% from ₹720 crore in Q2 FY26, and net profit for shareholders was ₹141 crore, up 43.8% from ₹98.3 crore. Marksans Pharma said QliniQ, a Dutch company it bought in 2026, added about ₹40 crore of the quarter's revenue. [S6, S10, S17]

**Does Marksans Pharma have debt?**

Marksans Pharma had ₹29.0 crore of borrowings and ₹1,124 crore of cash, bank balances and current investments on 30 Sep 2026. Marksans Pharma's lease liabilities, shown separately from borrowings, were ₹314 crore on 31 Mar 2026. [S6, S1]

**What dividend does Marksans Pharma pay?**

Marksans Pharma's board recommended a final dividend of ₹0.90 a share for FY26, against ₹0.80 for FY25 and ₹0.60 for FY24. The FY26 dividend comes to ₹40.8 crore. [S1, S2, S3, S44]

**What did Marksans Pharma buy in 2026?**

Marksans Pharma bought QliniQ B.V. of the Netherlands for EUR 7.50 million, a subsidiary from 1 Apr 2026, and ABCnow GmbH of Germany, a subsidiary from 1 Jul 2026, for EUR 1.10 million according to the Q2 FY27 results. [S37, S16]

## What does Marksans Pharma sell?

Marksans makes generic medicines: copies of medicines whose patents have ended, as tablets, capsules and soft-gel capsules. Most are sold without a prescription, often under a shop chain's own brand. The rest are prescription medicines, sold mainly in the UK, Australia and the US.

- **Over-the-counter (OTC) medicines:** Painkillers, cough-and-cold, digestive and allergy products that people buy without a prescription. The company's presentation put OTC at 80.0% of FY26 revenue. It says about 85% of OTC revenue came from store brands (shop chains' own labels) and the rest from its own labels, an approximate split. [S17]
- **Prescription generics:** Medicines a doctor prescribes, 20.0% of FY26 revenue. Relonchem holds 175+ UK marketing authorisations (licences to sell a medicine), and Nova Pharmaceuticals launched 11 branded prescription medicines in Australia and New Zealand in FY26. [S17]
- **Pain-management products:** The largest therapy group: ₹1,311 crore in FY26, 44.4% of revenue (Cityfort calculation from the company's presentation). CARE Ratings put pain management at about 45% of revenue and cough and cold at 13% in its Oct 2025 report. [S17, S35]

## Who pays Marksans Pharma?

- **Buyers in the US and North America (52.0% of revenue):** Mostly retail chains buying store-brand OTC medicines. CARE said in Oct 2025 that about 90% of FY25 US revenue was OTC and that retail chains gave nearly 80% of OTC revenue. The US and North America gave 52.0% of FY26 revenue. [S1, S35]
- **Buyers in Europe and the UK (34.4% of revenue):** Bell, Sons & Co. sells OTC medicines (450+ products) and Relonchem sells prescription generics in the UK; QliniQ (Netherlands) and ABCnow (Germany) joined in 2026. Europe and the UK gave 34.4% of FY26 revenue. [S1, S17]
- **Buyers in Australia and New Zealand (10.3% of revenue):** Nova Pharmaceuticals, 60% owned, sells OTC and branded prescription medicines. Australia and New Zealand gave 10.3% of FY26 revenue. [S1, S17]
- **Other countries, including India (3.4% of revenue):** About 10 countries in the CIS and the Middle East and North Africa. Other countries gave 3.4% of FY26 revenue. [S1, S17]
- **Customer concentration:** Two unnamed customers each gave at least 10% of FY26 revenue, ₹679.1 crore (23.0%) together; in FY24 and FY25 no single customer reached 10%. One customer was more than 10% of trade receivables on 31 Mar 2026. [S1, S2, S3]

## Where the money went (FY26)

1. In FY26 Marksans sold ₹2,951 crore of medicines and earned ₹82.5 crore of other income, including ₹50.1 crore of currency gains.
2. Materials and goods bought for resale took ₹1,277 crore, the biggest cost.
3. Other running costs took ₹652 crore and employees ₹421 crore.
4. Depreciation and interest took ₹123 crore, income tax ₹141 crore and Nova's minority holders ₹2.2 crore.
5. What was left was ₹418 crore of net profit for Marksans' shareholders.

Sources: S1, S16.

## Key numbers by year (₹ crore)

Financials: consolidated, ₹ crore. Financial year runs April to March (March year end). — = not shown on the page.

| Year | Revenue | EBITDA | EBITDA margin | Net profit | Net margin | EPS (₹ per share) | Operating cash flow | Capital spending | Free cash flow | Sources |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| FY22 | 1,490.8 | 258.9 | 17.4% | 184.6 | 12.4% | 4.51 | 99.3 | 46.3 | 52.9 | S4, S5 |
| FY23 | 1,852.1 | 339.3 | 18.3% | 266.3 | 14.4% | 6.41 | 237.4 | 53.6 | 183.8 | S3, S15 |
| FY24 | 2,177.4 | 458.6 | 21.1% | 313.7 | 14.4% | 6.92 | 230.4 | 208.8 | 21.6 | S3, S14 |
| FY25 (restated) | 2,622.8 | 532.7 | 20.3% | 380.6 | 14.5% | 8.4 | 206.7 | 172.9 | 33.7 | S1 |
| FY26 | 2,950.9 | 600.8 | 20.4% | 417.9 | 14.2% | 9.22 | 458.1 | 130.5 | 327.6 | S1, S8 |

- EBITDA = profit before interest, tax and wear-and-tear of assets.
- Net profit is the share belonging to the company's owners.

## Balance sheet (as of 30 Sep 2026, ₹ crore)

On 30 Sep 2026 cash, bank balances and current investments of ₹1,124 crore were ₹1,095 crore more than borrowings of ₹29.0 crore, the net cash figure the company's Q2 FY27 presentation also gives. [S6, S17, S1, S4, S35, S36]

| Item | Value |
| --- | --- |
| Total debt | 29 |
| Cash and investments | 1,123.6 |
| Net debt (debt minus cash) | −1,094.6 |
| Net worth (shareholders' money) | 3,332.3 |
| Debt to equity (times) | 0.01 |

- Borrowings are all short-term and were between ₹23 crore and ₹42 crore at every year end from Mar 2022 to Mar 2026.
- Lease liabilities are shown separately from borrowings: ₹314 crore on 31 Mar 2026, against ₹69.5 crore on 31 Mar 2022. Counting them, cash and investments exceeded borrowings and leases by ₹646 crore on 31 Mar 2026 (Cityfort calculation from the FY26 annual report).
- The FY26 annual report shows no contingent liabilities on 31 Mar 2026 or 31 Mar 2025.
- Inventories were ₹996 crore and trade receivables ₹757 crore on 30 Sep 2026.
- CARE Ratings upgraded the long-term bank facilities to CARE AA-; Stable on 6 Oct 2025, and India Ratings revised its outlook to Positive on 9 Jun 2026.
- Debt to equity = borrowings ÷ shareholders' equity of ₹3,332 crore (Cityfort calculation).

## Who owns Marksans Pharma? (shareholding, Q2 FY27)

| Holder | % of shares |
| --- | --- |
| Promoters | 43.87% |
| Promoter shares pledged (% of promoter shares) | 0.0% |
| Foreign institutions (FII) | 10.44% |
| Indian institutions (DII) | 5.54% |
| Public | 31.53% |
| OrbiMed Asia IV Mauritius (foreign direct investment) | 8.62% |

Sources: S23, S24, S25, S26, S27, S28, S29, S30, S31, S32, S33, S34.

## What could go wrong

### Two customers give almost a quarter of revenue

Two unnamed customers gave ₹679.1 crore, 23.0% of FY26 revenue; in FY24 and FY25 no single customer reached 10%. CARE said retail chains gave nearly 80% of US OTC revenue in FY25. [S1, S2, S3, S35]

What to watch: The customer note in the FY27 annual report.

### Falling prices for generic medicines

Management said on the 14 Nov 2025 call that the UK had seen tremendous price erosion, and Europe and UK revenue fell 1.4% in FY26. The company said US prescription price erosion stayed in single digits in Q2 FY27. [S22, S1, S17]

What to watch: Europe and UK revenue each quarter, with and without QliniQ.

### One therapy gives the biggest share

Pain-management products sold ₹1,311 crore, 44.4% of FY26 revenue (Cityfort calculation from the company's presentation). CARE called this a segment concentration risk in Oct 2025. [S17, S35]

What to watch: The therapy split in the company's presentations.

### Plant inspections by foreign regulators

Sales in the US, UK and Australia depend on plants their regulators approve. A subsidiary received a US FDA observation in Apr 2025, closed in Jun 2025, CARE said; the second Goa plant's Nov 2025 inspection ended with zero observations. [S35, S41]

What to watch: US FDA, UK MHRA and Australian TGA inspection results filed with the exchanges.

### US trade rules

The US and North America gave 52.0% of FY26 revenue. CARE said in Oct 2025 that a 100% US tariff on imported branded or patented medicines did not apply to generics, Marksans' main business, and that tariff developments would remain a key monitorable. [S1, S35]

What to watch: US tariff rules for generic medicines and US revenue each quarter.

### Currency moves

The Indian company exported 100% of its FY26 turnover, and other income included ₹50.1 crore of currency gains in FY26. CARE said the company's exposure is mainly in US dollars and euros. [S1, S16, S35]

What to watch: Currency gains or losses in the notes to each quarter's results.

### Fitting in new acquisitions

Goodwill rose from ₹45.3 crore on 31 Mar 2026 to ₹103 crore on 30 Sep 2026 after the QliniQ and ABCnow purchases, whose purchase price allocations are still provisional. [S6, S8, S16, S19]

What to watch: Final purchase price allocation and QliniQ's revenue against management's ₹150–175 crore expectation for FY27.

## What to watch

Next: Q3 FY27 results, Date not announced yet.

- **Customer concentration:** Two customers gave 23.0% of FY26 revenue; the FY27 annual report will show whether that share changed.
- **Growth without acquisitions:** The company put Q2 FY27 revenue growth without QliniQ at about 25%; ABCnow has been included since 1 Jul 2026.
- **The ₹4,000 crore target:** Management said on 27 May 2026 that its target was ₹4,000 crore of revenue in the next 2 years; FY26 revenue was ₹2,951 crore and H1 FY27 revenue ₹1,781 crore.

## Sources

- S1: Annual Report 2025-26 (FY26), incl. BRSR. Marksans Pharma Ltd (company IR site). https://www.marksanspharma.com/pdf/marksans-annual-report-2025-26.pdf (published 4 Aug 2026)
- S2: Annual Report 2024-25 (FY25). Marksans Pharma Ltd (company IR site). https://www.marksanspharma.com/pdf/annual-report/marksans-annual-report-2024-2025.pdf (published 16 Jul 2025)
- S3: Annual Report 2023-24 (FY24). Marksans Pharma Ltd (company IR site). https://www.marksanspharma.com/pdf/annual-report/marksans-annual-report-2023-2024.pdf (published 31 Aug 2024)
- S4: Annual Report 2022-23 (FY23). Marksans Pharma Ltd (company IR site). https://www.marksanspharma.com/pdf/annual-report/marksans-annual-report-22-23.pdf (published 8 Aug 2023)
- S5: Annual Report 2021-22 (FY22). Marksans Pharma Ltd (company IR site). https://www.marksanspharma.com/pdf/annual-report/annual-report-21-22.pdf (published 4 Aug 2022)
- S6: Consolidated results XBRL Q2 FY27, incl. half-year balance sheet and cash flow (integrated filing). NSE (XBRL). https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1752710_04112026051034_WEB.xml (published 4 Nov 2026)
- S7: Consolidated results XBRL Q1 FY27 (integrated filing). NSE (XBRL). https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1712406_12082026024755_WEB.xml (published 12 Aug 2026)
- S8: Consolidated results XBRL Q4 FY26 and FY26, incl. balance sheet and cash flow (integrated filing). NSE (XBRL). https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1673104_26052026043615_WEB.xml (published 26 May 2026)
- S9: Consolidated results XBRL Q3 FY26 (integrated filing). NSE (XBRL). https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1619110_05022026044708_WEB.xml (published 5 Feb 2026)
- S10: Consolidated results XBRL Q2 FY26, incl. half-year balance sheet and cash flow (integrated filing). NSE (XBRL). https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1574289_13112025083433_WEB.xml (published 13 Nov 2025)
- S11: Consolidated results XBRL Q1 FY26 (integrated filing). NSE (XBRL). https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1509382_12082025032311_WEB.xml (published 12 Aug 2025)
- S13: Consolidated results XBRL Q3 FY25 and 9M FY25. NSE (XBRL). https://nsearchives.nseindia.com/corporate/xbrl/INDAS_119754_1378919_11022025101133.xml (published 11 Feb 2025)
- S14: Consolidated results XBRL Q4 FY24 and FY24, incl. balance sheet and cash flow. NSE (XBRL). https://nsearchives.nseindia.com/corporate/xbrl/INDAS_108302_1148361_30052024062026.xml (published 30 May 2024)
- S15: Consolidated results XBRL Q4 FY23 and FY23, incl. balance sheet and cash flow. NSE (XBRL). https://nsearchives.nseindia.com/corporate/xbrl/INDAS_93775_859618_31052023121351.xml (published 31 May 2023)
- S16: Outcome of board meeting: unaudited results Q2 FY27 (standalone and consolidated). Marksans Pharma Ltd (company IR site). https://www.marksanspharma.com/pdf/outcome-of-board-meeting-november-2026.pdf (published 4 Nov 2026)
- S17: Earnings presentation Q2 & H1 FY27. Marksans Pharma Ltd (company IR site). https://www.marksanspharma.com/pdf/investors-presentation-september-2026.pdf (published 4 Nov 2026)
- S19: Earnings call transcript Q1 FY27 (call 13 Aug 2026). Marksans Pharma Ltd (company IR site). https://www.marksanspharma.com/pdf/transcript-q1-fy-27.pdf (published 20 Aug 2026)
- S20: Earnings call transcript Q4 FY26 (call 27 May 2026). Marksans Pharma Ltd (company IR site). https://www.marksanspharma.com/pdf/Q4FY26-earnings-call-transcrip.pdf (published 3 Jun 2026)
- S21: Earnings call transcript Q3 FY26 (call 6 Feb 2026). Marksans Pharma Ltd (company IR site). https://www.marksanspharma.com/pdf/Q3FY26-earnings-call-transcrip.pdf (published 12 Feb 2026)
- S22: Earnings call transcript Q2 FY26 (call 14 Nov 2025). Marksans Pharma Ltd (company IR site). https://www.marksanspharma.com/pdf/q2-fy26-earnings-call-transcript.pdf (published 21 Nov 2025)
- S23: Shareholding pattern Dec-23 (XBRL). NSE (XBRL). https://nsearchives.nseindia.com/corporate/xbrl/SHP_184455_1024075_17012024114524_WEB.xml (published 17 Jan 2024)
- S24: Shareholding pattern Mar-24 (XBRL). NSE (XBRL). https://nsearchives.nseindia.com/corporate/xbrl/SHP_186797_1092460_15042024051235_WEB.xml (published 15 Apr 2024)
- S25: Shareholding pattern Jun-24 (XBRL). NSE (XBRL). https://nsearchives.nseindia.com/corporate/xbrl/SHP_189259_1182301_12072024040604_WEB.xml (published 12 Jul 2024)
- S26: Shareholding pattern Sep-24 (XBRL). NSE (XBRL). https://nsearchives.nseindia.com/corporate/xbrl/SHP_192511_1274441_17102024025500_WEB.xml (published 17 Oct 2024)
- S27: Shareholding pattern Dec-24 (XBRL). NSE (XBRL). https://nsearchives.nseindia.com/corporate/xbrl/SHP_194419_1343347_13012025125633_WEB.xml (published 13 Jan 2025)
- S28: Shareholding pattern Mar-25 (XBRL). NSE (XBRL). https://nsearchives.nseindia.com/corporate/xbrl/SHP_196808_1412135_11042025104646_WEB.xml (published 11 Apr 2025)
- S29: Shareholding pattern Jun-25 (XBRL). NSE (XBRL). https://nsearchives.nseindia.com/corporate/xbrl/SHP_1486096_18072025110817_WEB.xml (published 18 Jul 2025)
- S30: Shareholding pattern Sep-25 (XBRL). NSE (XBRL). https://nsearchives.nseindia.com/corporate/xbrl/SHP_1551945_17102025041829_WEB.xml (published 17 Oct 2025)
- S31: Shareholding pattern Dec-25 (XBRL); revised file of 19 May 2026. NSE (XBRL). https://nsearchives.nseindia.com/corporate/xbrl/SHP_1669180_19052026025021_WEB.xml (published 13 Jan 2026)
- S32: Shareholding pattern Mar-26 (XBRL). NSE (XBRL). https://nsearchives.nseindia.com/corporate/xbrl/SHP_1648616_10042026022024_WEB.xml (published 10 Apr 2026)
- S33: Shareholding pattern Jun-26 (XBRL). NSE (XBRL). https://nsearchives.nseindia.com/corporate/xbrl/SHP_1696395_20072026103809_WEB.xml (published 20 Jul 2026)
- S34: Shareholding pattern Sep-26 (XBRL). NSE (XBRL). https://nsearchives.nseindia.com/corporate/xbrl/SHP_1738573_15102026123752_WEB.xml (published 15 Oct 2026)
- S35: CARE Ratings: upgrade to CARE AA-; Stable / CARE A1+ (press release attached to company intimation). Marksans Pharma Ltd (NSE filing). https://nsearchives.nseindia.com/corporate/MARKSANS_08102025110322_MPL_Intimation_Signed.pdf (published 8 Oct 2025)
- S36: Intimation: India Ratings outlook revised to Positive, IND AA-/IND A1+ affirmed. Marksans Pharma Ltd (NSE filing). https://nsearchives.nseindia.com/corporate/MARKSANS_09062026151057_SEIntimation.pdf (published 9 Jun 2026)
- S37: Press release and Reg. 30 disclosure: agreement to acquire QliniQ B.V.. Marksans Pharma Ltd (NSE filing). https://nsearchives.nseindia.com/corporate/MARKSANS_01062026090042_SEIntimation.pdf (published 1 Jun 2026)
- S40: Completion of ABCnow GmbH acquisition. Marksans Pharma Ltd (NSE filing). https://nsearchives.nseindia.com/corporate/MARKSANS_20072026171817_Closing_intimation.pdf (published 20 Jul 2026)
- S41: US FDA cGMP inspection at 2nd Goa facility (Verna) closed with zero Form 483 observations. Marksans Pharma Ltd (NSE filing). https://nsearchives.nseindia.com/corporate/MARKSANS_10112025121905_SEIntimation.pdf (published 10 Nov 2025)
- S42: Australian TGA approval for Verna (Goa) facility. Marksans Pharma Ltd (NSE filing). https://nsearchives.nseindia.com/corporate/MARKSANS_20032025112627_SEIntimation.pdf (published 20 Mar 2025)
- S43: Allotment of 56,250 shares under ESOP Scheme 2024. Marksans Pharma Ltd (NSE filing). https://nsearchives.nseindia.com/corporate/MARKSANS_04112026170050_SEIntimation.pdf (published 4 Nov 2026)
- S44: Outcome of board meeting 26 May 2026: audited FY26 results and final dividend ₹0.90 a share. Marksans Pharma Ltd (NSE filing). https://nsearchives.nseindia.com/corporate/MARKSANS_26052026131505_Outcome_of_BM.pdf (published 26 May 2026)
- S46: NSE historical price data MARKSANS (EQ), 2–11 Nov 2026; close ₹306.55 on 11 Nov 2026. NSE. https://www.nseindia.com/api/historicalOR/generateSecurityWiseHistoricalData?from=01-11-2026&to=12-11-2026&symbol=MARKSANS&type=priceVolumeDeliverable&series=ALL (published 11 Nov 2026)
- S49: Outcome of board meeting 19 May 2025: audited results Q4 FY25 and FY25 (standalone and consolidated; scanned). Marksans Pharma Ltd (company IR site). https://www.marksanspharma.com/pdf/outcome-of-board-meeting-may-2025.pdf (published 19 May 2025)
